Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma

HIGHLIGHTS

• who: Lulu Liu et al. from the Italy Heinrich Heine University of Du00fcsseldorf have published the paper: Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma, in the Journal: (JOURNAL)
• what: The aim of the study is to estimate the costeffectiveness of sintilimab plus chemotherapy vs chemotherapy alone as first-line treatment for patients with advanced or metastatic OSCC based on the ORIENT-15 trial data from the perspective of Chinese healthcare system. Third, clinical benefits beyond the observation time of the . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.